Mizuho Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $250.00

Palvella Therapeutics (NASDAQ:PVLA) had its target price increased by stock analysts at Mizuho from $205.00 to $250.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price target would suggest a potential upside of 68.53% from the company’s current price.

Several other research analysts also recently issued reports on the company. Chardan Capital upped their price objective on Palvella Therapeutics from $174.00 to $210.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald raised their price target on Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Craig Hallum initiated coverage on Palvella Therapeutics in a report on Thursday, December 4th. They set a “buy” rating and a $175.00 price objective for the company. Finally, Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Palvella Therapeutics has an average rating of “Buy” and an average price target of $176.44.

Palvella Therapeutics Trading Up 15.3%

Shares of NASDAQ PVLA opened at $148.34 on Wednesday. Palvella Therapeutics has a 1-year low of $18.23 and a 1-year high of $151.18. The company has a 50-day moving average of $93.82 and a two-hundred day moving average of $79.34. The company has a market cap of $1.76 billion, a PE ratio of -56.40 and a beta of -0.16.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Archer Investment Corp acquired a new position in Palvella Therapeutics in the third quarter valued at about $28,000. Group One Trading LLC raised its position in shares of Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Palvella Therapeutics during the 3rd quarter valued at about $36,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Palvella Therapeutics in the 2nd quarter valued at approximately $37,000. Finally, JPMorgan Chase & Co. increased its stake in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Trending Headlines about Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 / late‑stage clinical news has driven investor enthusiasm — coverage and headlines about a late‑stage win for Palvella’s lead asset are cited as a major momentum driver. Palvella Therapeutics shares surge on positive Phase 3 trial results
• Positive Sentiment: HC Wainwright materially raised multi‑year EPS forecasts and bumped its price target to $255 (from $200), and the firm retains a Buy — analyst upgrades and a hawkish target boost sentiment and institutional interest. Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright
• Positive Sentiment: Other firms have increased targets (Mizuho $250, BTIG $215, Chardan $210), signaling broad analyst conviction and adding buying pressure from funds tracking upgrades. Chardan Capital Boosts Palvella Therapeutics Price Target to $210.00
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 to raise roughly $200M (plus a 30‑day option on 240k shares). The proceeds will fund QTORIN programs and R&D (cash runway positive), but the issuance dilutes current shareholders and adds near‑term supply. Palvella Therapeutics Announces Pricing of Upsized Public Offering
• Negative Sentiment: Short interest rose ~22% in February to about 1.67M shares (~17.8% of float) with ~5.5 days to cover; sizable short positions can pressure the stock if trial/clinical timelines slip, though they can also amplify rallies in the near term. Insider sales have also been reported, which some investors view negatively. (No single article link provided in the feed.)

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.